PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Researchers find potential new treatment approach for pancreatic cancer

Scientists from The University of Manchester -- part of Manchester Cancer Research Centre believe they have discovered a new way to make chemotherapy treatment more effective for pancreatic cancer patients

2013-12-21
(Press-News.org) Contact information: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester
Researchers find potential new treatment approach for pancreatic cancer Scientists from The University of Manchester -- part of Manchester Cancer Research Centre believe they have discovered a new way to make chemotherapy treatment more effective for pancreatic cancer patients

Scientists from The University of Manchester – part of Manchester Cancer Research Centre believe they have discovered a new way to make chemotherapy treatment more effective for pancreatic cancer patients.

Pancreatic cancer is an aggressive cancer with poor prognosis and limited treatment options and is highly resistant to chemotherapy and radiotherapy.

But researchers believe they have found an effective strategy for selectively killing pancreatic cancer while sparing healthy cells which could make treatment more effective.

Dr Jason Bruce, from the Physiological Systems and Disease Research Group, who led the research, said: "Pancreatic cancer is one of the most aggressive and deadly cancers. Most patients develop symptoms after the tumour has spread to other organs. To make things worse, pancreatic cancer is highly resistant to chemotherapy and radiotherapy. Clearly a radical new approach to treatment is urgently required. We wanted to understand how the switch in energy supply in cancer cells might help them survive."

The research, published in The Journal of Biological Chemistry this month, found pancreatic cancer cells may have their own specialised energy supply that maintains calcium levels and keeps cancer cells alive.

Maintaining a low concentration of calcium within cells is vital to their survival and this is achieved by calcium pumps on the plasma membrane.

This calcium pump, known as PMCA, is fuelled using ATP – the key energy currency for many cellular processes.

All cells generate energy from nutrients using two major biochemical energy "factories", mitochondria and glycolysis. Mitochondria generate approximately 90% of the cells' energy in normal healthy cells. However, in pancreatic cancer cells there is a shift towards glycolysis as the major energy source. It is thought that the calcium pump may have its own supply of glycolytic ATP, and it is this fuel supply that gives cancer cells a survival advantage over normal cells.

Scientists used cells taken from human tumours and looked at the effect of blocking each of these two energy sources in turn.

Their study, funded by the Biotechnology and Biological Sciences Research Council (BBSRC), Central Manchester University Hospitals NHS Foundation Trust (CMFT)/National Institute of Health Research (NIHR) Manchester Biomedical Research Centre and AstraZeneca, shows that blocking mitochondrial metabolism had no effect. However, when they blocked glycolysis, they saw a reduced supply of ATP which inhibited the calcium pump, resulting in a toxic calcium overload and ultimately cell death.

Dr Bruce added: "It looks like glycolysis is the key process in providing ATP fuel for the calcium pump in pancreatic cancer cells. Although an important strategy for cell survival, it may also be their major weakness.

"Designing drugs to cut off this supply to the calcium pumps might be an effective strategy for selectively killing cancer cells while sparing normal cells within the pancreas."

Maggie Blanks, CEO of the national charity, the Pancreatic Cancer Research Fund said: "These findings will certainly of great interest to the pancreatic cancer research community and we'd be keen to see how this approach progresses. Finding weaknesses that can be exploited in this highly aggressive cancer is paramount, so we want to congratulate the Manchester team for their discovery."



INFORMATION:



ELSE PRESS RELEASES FROM THIS DATE:

Wayne State cholesterol study shows algal extracts may counter effects of high fat diets

2013-12-21
Wayne State cholesterol study shows algal extracts may counter effects of high fat diets Health Enhancement Products, Inc. (OTC.BB:HEPI.OB – News), in conjunction with Wayne State University's Department of Nutrition ...

Staph stoppers

2013-12-21
Staph stoppers New vaccine from University of Iowa protects against lethal pneumonia caused by staph bacteria University of Iowa researchers have developed a new vaccine that protects against lethal pneumonia caused by Staphylococcus aureus (staph) bacteria, including ...

A wrong molecular turn leads down the path to Type 2 diabetes

2013-12-21
A wrong molecular turn leads down the path to Type 2 diabetes Computing resources at the U.S. Department of Energy's (DOE) Argonne National Laboratory have helped researchers better grasp how proteins misfold to create the tissue-damaging structures that ...

UNL research raises concerns about global crop projections

2013-12-21
UNL research raises concerns about global crop projections 30 percent of world's corn, rice and wheat crop land may be 'maxed out' LINCOLN, Neb. — About 30 percent of the major global cereal crops – rice, wheat and corn – may have reached their maximum possible ...

Penn researchers grow liquid crystal 'flowers' that can be used as lenses

2013-12-21
Penn researchers grow liquid crystal 'flowers' that can be used as lenses A team of material scientists, chemical engineers and physicists from the University of Pennsylvania has made another advance in their effort to use liquid crystals as a medium for assembling ...

NASA sees powerful Tropical Cyclone Bruce staying away from land

2013-12-21
NASA sees powerful Tropical Cyclone Bruce staying away from land Tropical Cyclone Bruce continued to strengthen over wide open waters of the Southern Indian Ocean and NASA satellite data showed its eye had cleared of clouds. Bruce is forecast to stay away from ...

Religion is good for business shows Rotman study

2013-12-21
Religion is good for business shows Rotman study Toronto – Those looking for honest companies to invest in might want to check out businesses based in more religious communities, suggests a new paper from the University of ...

Not just the Koch brothers: New Drexel study reveals funders behind the climate change denial effort

2013-12-21
Not just the Koch brothers: New Drexel study reveals funders behind the climate change denial effort A new study conducted by Drexel University's environmental sociologist Robert J. Brulle, PhD, exposes the organizational underpinnings and funding behind the powerful ...

NASA satellites see Tropical Cyclone Amara affecting Rodrigues Island

2013-12-21
NASA satellites see Tropical Cyclone Amara affecting Rodrigues Island When NASA's Terra satellite passed over Tropical Cyclone Amara on December 20, its western quadrant was already moving over Rodrigues Island, Mauritius. Warnings are already in effect for the island, ...

Even or odd: No easy feat for the mind

2013-12-21
Even or odd: No easy feat for the mind MADISON — Even scientists are fond of thinking of the human brain as a computer, following sets of rules to communicate, make decisions and find a meal. But if the brain is like a computer, why do brains make mistakes ...

LAST 30 PRESS RELEASES:

Dr. Gianluca Ianiro wins a prestigious grant from the European Research Council (ERC)

‘Rogue’ DNA rings reveal earliest clues to deadly brain cancer’s growth

Clinical study deepens understanding of mesothelioma and opens the door to potential treatment options

New study and major data updates expand the Kids First data ecosystem

Seaweed snare: Sargassum stops sea turtle hatchlings in their tracks

Scientists uncover key to decoupling economic growth from pollution in developing countries

Frailty fuels gut imbalance and post-surgery gastrointestinal risks

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and lower toxicity to conventional schedule in LS-SCLC

Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds

Video assisted thoracoscopy surgery reduces mortality by 21 percent compared to lobectomy

NADIM ADJUVANT trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

EA5181 phase 3 trial finds no OS benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable stage 3 NSCLC

Training to improve memory

Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use?

Black youth, especially Black girls, use mental health services less than their White peers

Canada must protect youth from sports betting advertising

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

Higher blood pressure in childhood linked to earlier death from heart disease in adulthood

AI helped older adults report accurate blood pressure readings at home

High blood pressure in childhood and premature cardiovascular disease mortality

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC

[Press-News.org] Researchers find potential new treatment approach for pancreatic cancer
Scientists from The University of Manchester -- part of Manchester Cancer Research Centre believe they have discovered a new way to make chemotherapy treatment more effective for pancreatic cancer patients